metreleptin (Myalepta)
Jump to navigation
Jump to search
Indications
- generalized lipodystrophy (FDA-approved Feb 2014)
- leptin deficiency[3]
Contraindications
- hypertriglyceridemia associated with diabetes mellitus
- HIV1-related lipodystrophy
- generalized obesity
Dosage
- 11.3 mg powder for injectable solution
Adverse effects
- hypoglycemia
- weight loss
- injection site reactions
- formation of neutralizing antibodies.
Mechanism of action
- recombinant human leptin analog
- binds to & activates human leptin receptor
- decreases different types of fat in the body
- reduces fat accumulation in tissues, including liver & muscle
- lowers glycated hemoglobin & serum triglycerides in patients with lipodystrophy
More general terms
References
- ↑ Medscape: Feb 25, 2014 Myalept (Metreleptin) Approved for Generalized Lipodystrophy. http://www.medscape.com/viewarticle/821056
- ↑ Chou K1, Perry CM. Metreleptin: first global approval. Drugs. 2013 Jun;73(9):989-97. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23740412
- ↑ 3.0 3.1 Brown T EMA Panel Recommends Metreleptin for Leptin Deficiency. Medscape - Jun 01, 2018. https://www.medscape.com/viewarticle/897471